(GRFS) Grifols - Overview
Stock: Immunoglobulin, Albumin, Clotting Factors, Diagnostic Equipment, Plasma
Dividends
| Dividend Yield | 1.63% |
| Yield on Cost 5y | 1.04% |
| Yield CAGR 5y | -21.52% |
| Payout Consistency | 65.6% |
| Payout Ratio | 27.1% |
| Risk 5d forecast | |
|---|---|
| Volatility | 50.5% |
| Relative Tail Risk | -18.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.90 |
| Alpha | 19.49 |
| Character TTM | |
|---|---|
| Beta | 0.870 |
| Beta Downside | 0.960 |
| Drawdowns 3y | |
|---|---|
| Max DD | 52.68% |
| CAGR/Max DD | -0.01 |
Description: GRFS Grifols January 07, 2026
Grifols S.A. is a global plasma-therapeutics firm headquartered in Barcelona that extracts, processes, and markets plasma-derived medicines-including immunoglobulins, albumin, clotting factors, and specialty proteins such as alpha-1-antitrypsin-and also supplies diagnostic reagents and plasma to third-party manufacturers. Its product portfolio spans immunology, hematology, pulmonology, and surgical-bleeding indications, with a pipeline of pre-filled syringes, biosimilars, and novel biologics in various clinical stages.
Key operating metrics that signal the company’s scale and growth trajectory include: 2023 total revenue of roughly $2.5 billion, driven by a 9 % year-over-year increase in plasma collection volumes (≈12 million L) and a 6 % rise in net product sales; an operating margin of about 14 % reflecting cost-discipline in plasma processing; and a cash-rich balance sheet with net debt under $300 million, providing flexibility for pipeline investment. The plasma-derived therapeutics sector is buoyed by demographic aging, rising prevalence of rare immunodeficiencies, and stable reimbursement frameworks in the United States-the world’s largest market, which accounts for >60 % of Grifols’ sales.
For a deeper dive into Grifols’ valuation dynamics and how they compare with peer benchmarks, you may find ValueRay’s analytical tools useful.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 372.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 2.85 > 1.0 |
| NWC/Revenue: 42.62% < 20% (prev 42.36%; Δ 0.26% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.13b > Net Income 372.7m |
| Net Debt (9.10b) to EBITDA (1.55b): 5.88 < 3 |
| Current Ratio: 2.48 > 1.5 & < 3 |
| Outstanding Shares: last quarter (680.5m) vs 12m ago 0.13% < -2% |
| Gross Margin: 39.46% > 18% (prev 0.39%; Δ 3907 % > 0.5%) |
| Asset Turnover: 37.40% > 50% (prev 34.54%; Δ 2.86% > 0%) |
| Interest Coverage Ratio: 2.58 > 6 (EBITDA TTM 1.55b / Interest Expense TTM 467.0m) |
Altman Z'' 1.87
| A: 0.16 (Total Current Assets 5.37b - Total Current Liabilities 2.16b) / Total Assets 19.92b |
| B: 0.01 (Retained Earnings 201.7m / Total Assets 19.92b) |
| C: 0.06 (EBIT TTM 1.21b / Avg Total Assets 20.10b) |
| D: 0.36 (Book Value of Equity 4.40b / Total Liabilities 12.35b) |
| Altman-Z'' Score: 1.87 = BBB |
Beneish M -3.02
| DSRI: 1.02 (Receivables 1.10b/1.01b, Revenue 7.52b/7.01b) |
| GMI: 0.99 (GM 39.46% / 39.04%) |
| AQI: 0.99 (AQ_t 0.57 / AQ_t-1 0.58) |
| SGI: 1.07 (Revenue 7.52b / 7.01b) |
| TATA: -0.04 (NI 372.7m - CFO 1.13b) / TA 19.92b) |
| Beneish M-Score: -3.02 (Cap -4..+1) = AA |
What is the price of GRFS shares?
Over the past week, the price has changed by +0.32%, over one month by +0.98%, over three months by +11.00% and over the past year by +34.96%.
Is GRFS a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the GRFS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 12.5 | 35% |
| Analysts Target Price | 12.5 | 35% |
| ValueRay Target Price | 10.4 | 12.2% |
GRFS Fundamental Data Overview February 03, 2026
P/E Trailing = 13.8095
P/E Forward = 11.1982
P/S = 1.0151
P/B = 1.0143
P/EG = 0.229
Revenue TTM = 7.52b EUR
EBIT TTM = 1.21b EUR
EBITDA TTM = 1.55b EUR
Long Term Debt = 8.42b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 597.0m EUR (from shortTermDebt, last quarter)
Debt = 9.72b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.10b EUR (from netDebt column, last quarter)
Enterprise Value = 15.37b EUR (6.48b + Debt 9.72b - CCE 825.5m)
Interest Coverage Ratio = 2.58 (Ebit TTM 1.21b / Interest Expense TTM 467.0m)
EV/FCF = 18.06x (Enterprise Value 15.37b / FCF TTM 851.2m)
FCF Yield = 5.54% (FCF TTM 851.2m / Enterprise Value 15.37b)
FCF Margin = 11.32% (FCF TTM 851.2m / Revenue TTM 7.52b)
Net Margin = 4.96% (Net Income TTM 372.7m / Revenue TTM 7.52b)
Gross Margin = 39.46% ((Revenue TTM 7.52b - Cost of Revenue TTM 4.55b) / Revenue TTM)
Gross Margin QoQ = 40.29% (prev 39.33%)
Tobins Q-Ratio = 0.77 (Enterprise Value 15.37b / Total Assets 19.92b)
Interest Expense / Debt = 1.61% (Interest Expense 156.1m / Debt 9.72b)
Taxrate = 27.61% (54.7m / 198.1m)
NOPAT = 872.9m (EBIT 1.21b * (1 - 27.61%))
Current Ratio = 2.48 (Total Current Assets 5.37b / Total Current Liabilities 2.16b)
Debt / Equity = 1.87 (Debt 9.72b / totalStockholderEquity, last quarter 5.20b)
Debt / EBITDA = 5.88 (Net Debt 9.10b / EBITDA 1.55b)
Debt / FCF = 10.69 (Net Debt 9.10b / FCF TTM 851.2m)
Total Stockholder Equity = 5.47b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.85% (Net Income 372.7m / Total Assets 19.92b)
RoE = 6.81% (Net Income TTM 372.7m / Total Stockholder Equity 5.47b)
RoCE = 8.68% (EBIT 1.21b / Capital Employed (Equity 5.47b + L.T.Debt 8.42b))
RoIC = 6.30% (NOPAT 872.9m / Invested Capital 13.86b)
WACC = 4.34% (E(6.48b)/V(16.19b) * Re(9.12%) + D(9.72b)/V(16.19b) * Rd(1.61%) * (1-Tc(0.28)))
Discount Rate = 9.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.10%
[DCF Debug] Terminal Value 88.43% ; FCFF base≈625.9m ; Y1≈772.1m ; Y5≈1.31b
Fair Price DCF = 113.1 (EV 38.29b - Net Debt 9.10b = Equity 29.20b / Shares 258.2m; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 62.72 | EPS CAGR: 17.98% | SUE: -1.39 | # QB: 0
Revenue Correlation: 81.83 | Revenue CAGR: 13.48% | SUE: 0.04 | # QB: 0
EPS next Year (2026-12-31): EPS=1.30 | Chg30d=-0.039 | Revisions Net=-1 | Growth EPS=+49.4% | Growth Revenue=+5.6%